NASDAQ:ESRX - Express Scripts Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$92.33
+0.30 (1.20%)
Get New Express Scripts Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ESRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ESRX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Express Scripts in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $92.33.

This chart shows the closing price for ESRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Express Scripts. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/5/2018MizuhoSet Price TargetHold$101.00Low
11/2/2018CowenReiterated RatingBuy$88.00Low
11/1/2018BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$83.00 ➝ $90.00Low
11/1/2018Royal Bank of CanadaSet Price TargetBuy$101.00Medium
11/1/2018SVB LeerinkSet Price TargetMarket Perform ➝ Hold$95.00 ➝ $100.00Medium
11/1/2018Maxim GroupReiterated RatingHoldLow
10/31/2018William BlairDowngradeOutperform ➝ Market PerformLow
9/18/2018Credit Suisse GroupDowngradeOutperform ➝ Neutral$90.00 ➝ $96.50Low
8/27/2018Royal Bank of CanadaBoost Price TargetOutperform$94.00High
8/1/2018William BlairUpgradeMarket Perform ➝ OutperformLow
7/20/2018Robert W. BairdDowngradeOutperform ➝ Neutral$81.00Medium
5/17/2018Robert W. BairdSet Price TargetBuy$92.00Low
5/3/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$84.00 ➝ $83.00High
5/3/2018SVB LeerinkLower Price TargetMarket Perform$90.00 ➝ $80.00Medium
3/12/2018Sanford C. BernsteinUpgradeUnderperform ➝ Market PerformMedium
3/9/2018Wells Fargo & CompanyUpgradeUnderperform ➝ Market PerformLow
3/8/2018Raymond JamesUpgradeUnderperform ➝ Market PerformLow
3/8/2018MizuhoSet Price TargetHold$96.00Low
3/8/2018William BlairDowngradeOutperform ➝ Market PerformLow
3/8/2018Jefferies Financial GroupDowngradeBuy ➝ Hold$91.00High
3/8/2018Maxim GroupDowngradeBuy ➝ HoldHigh
3/8/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$84.00High
2/28/2018Maxim GroupBoost Price Target$87.00 ➝ $101.00Medium
2/28/2018Jefferies Financial GroupSet Price TargetPositive ➝ Buy$91.00High
2/27/2018Bank of AmericaInitiated CoverageUnderperform ➝ Underperform$77.00Medium
2/26/2018Maxim GroupReiterated RatingBuy$87.00Low
1/31/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$68.00Low
1/30/2018Sanford C. BernsteinDowngradeMarket Perform ➝ Underperform$55.80 ➝ $77.50Low
1/24/2018MizuhoSet Price TargetHold$86.00Low
1/12/2018SunTrust BanksReiterated RatingBuy$95.00Low
1/9/2018Robert W. BairdReiterated RatingOutperform ➝ Buy$81.00 ➝ $92.00N/A
1/4/2018Evercore ISIInitiated CoverageIn ➝ In-Line$78.00Low
12/21/2017SunTrust BanksSet Price TargetBuy$86.00Low
12/21/2017Needham & Company LLCReiterated RatingHoldLow
12/15/2017Jefferies Financial GroupSet Price TargetBuy$80.00High
12/15/2017Royal Bank of CanadaSet Price TargetHold$68.00High
12/15/2017Raymond JamesReiterated RatingSellLow
12/15/2017Robert W. BairdUpgradeNeutral ➝ Outperform$72.00 ➝ $81.00High
12/14/2017SunTrust BanksSet Price TargetBuy$82.00High
12/14/2017Maxim GroupBoost Price TargetBuy$78.00 ➝ $87.00Low
12/6/2017Sanford C. BernsteinUpgradeUnderperform ➝ Market PerformLow
12/4/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$75.00High
10/26/2017Jefferies Financial GroupReiterated RatingBuyN/A
10/25/2017Royal Bank of CanadaSet Price TargetHold$66.00N/A
10/25/2017Robert W. BairdBoost Price TargetNeutral$57.00 ➝ $59.00N/A
10/24/2017MizuhoSet Price TargetHold$67.00N/A
10/9/2017Raymond JamesReiterated RatingMarket Perform ➝ UnderperformN/A
10/9/2017UBS GroupDowngradeMarket Perform ➝ UnderperformN/A
9/19/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$68.00High
9/1/2017Robert W. BairdReiterated RatingHold$56.00Medium
8/29/2017Jefferies Financial GroupSet Price TargetBuy$72.00Low
8/10/2017Morgan StanleyBoost Price TargetUnderweight$52.00 ➝ $57.00Low
7/21/2017Needham & Company LLCInitiated CoverageHold ➝ HoldLow
6/9/2017CowenReiterated RatingOutperform$83.00Low
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Express Scripts logo
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.
Read More

Today's Range

Now: $92.33
Low: $92.11
High: $95.87

50 Day Range

MA: $92.33
Low: $92.33
High: $92.33

52 Week Range

Now: $92.33
Low: $66.93
High: $101.73

Volume

31,612,912 shs

Average Volume

6,636,970 shs

Market Capitalization

$52.06 billion

P/E Ratio

13.00

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Express Scripts?

The following Wall Street sell-side analysts have issued stock ratings on Express Scripts in the last twelve months:
View the latest analyst ratings for ESRX.

What is the current price target for Express Scripts?

0 Wall Street analysts have set twelve-month price targets for Express Scripts in the last year.
View the latest price targets for ESRX.

What is the current consensus analyst rating for Express Scripts?

Express Scripts currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ESRX.

What other companies compete with Express Scripts?

How do I contact Express Scripts' investor relations team?

Express Scripts' physical mailing address is ONE EXPRESS WAY, SAINT LOUIS MO, 63121. The company's listed phone number is 314-996-0900 and its investor relations email address is [email protected] The official website for Express Scripts is www.express-scripts.com. Learn More about contacing Express Scripts investor relations.